S&P 500   3,451.49 (+0.72%)
DOW   28,388.71 (+0.69%)
QQQ   285.75 (+0.69%)
AAPL   117.21 (+1.06%)
MSFT   216.95 (+1.27%)
FB   266.34 (+1.89%)
GOOGL   1,550.37 (+1.33%)
AMZN   3,238.78 (+0.98%)
TSLA   422.43 (-1.95%)
NVDA   546.96 (+1.31%)
BABA   310.18 (+1.60%)
CGC   18.76 (-5.30%)
GE   7.32 (+0.41%)
MU   53.36 (+1.39%)
AMD   82.28 (+0.34%)
T   26.93 (+0.19%)
F   7.74 (+1.98%)
ACB   4.28 (-9.13%)
GILD   60.24 (-0.54%)
NFLX   528.70 (-0.38%)
BA   167.10 (+-0.01%)
BAC   24.16 (+1.85%)
DIS   125.05 (+0.66%)
S&P 500   3,451.49 (+0.72%)
DOW   28,388.71 (+0.69%)
QQQ   285.75 (+0.69%)
AAPL   117.21 (+1.06%)
MSFT   216.95 (+1.27%)
FB   266.34 (+1.89%)
GOOGL   1,550.37 (+1.33%)
AMZN   3,238.78 (+0.98%)
TSLA   422.43 (-1.95%)
NVDA   546.96 (+1.31%)
BABA   310.18 (+1.60%)
CGC   18.76 (-5.30%)
GE   7.32 (+0.41%)
MU   53.36 (+1.39%)
AMD   82.28 (+0.34%)
T   26.93 (+0.19%)
F   7.74 (+1.98%)
ACB   4.28 (-9.13%)
GILD   60.24 (-0.54%)
NFLX   528.70 (-0.38%)
BA   167.10 (+-0.01%)
BAC   24.16 (+1.85%)
DIS   125.05 (+0.66%)
S&P 500   3,451.49 (+0.72%)
DOW   28,388.71 (+0.69%)
QQQ   285.75 (+0.69%)
AAPL   117.21 (+1.06%)
MSFT   216.95 (+1.27%)
FB   266.34 (+1.89%)
GOOGL   1,550.37 (+1.33%)
AMZN   3,238.78 (+0.98%)
TSLA   422.43 (-1.95%)
NVDA   546.96 (+1.31%)
BABA   310.18 (+1.60%)
CGC   18.76 (-5.30%)
GE   7.32 (+0.41%)
MU   53.36 (+1.39%)
AMD   82.28 (+0.34%)
T   26.93 (+0.19%)
F   7.74 (+1.98%)
ACB   4.28 (-9.13%)
GILD   60.24 (-0.54%)
NFLX   528.70 (-0.38%)
BA   167.10 (+-0.01%)
BAC   24.16 (+1.85%)
DIS   125.05 (+0.66%)
S&P 500   3,451.49 (+0.72%)
DOW   28,388.71 (+0.69%)
QQQ   285.75 (+0.69%)
AAPL   117.21 (+1.06%)
MSFT   216.95 (+1.27%)
FB   266.34 (+1.89%)
GOOGL   1,550.37 (+1.33%)
AMZN   3,238.78 (+0.98%)
TSLA   422.43 (-1.95%)
NVDA   546.96 (+1.31%)
BABA   310.18 (+1.60%)
CGC   18.76 (-5.30%)
GE   7.32 (+0.41%)
MU   53.36 (+1.39%)
AMD   82.28 (+0.34%)
T   26.93 (+0.19%)
F   7.74 (+1.98%)
ACB   4.28 (-9.13%)
GILD   60.24 (-0.54%)
NFLX   528.70 (-0.38%)
BA   167.10 (+-0.01%)
BAC   24.16 (+1.85%)
DIS   125.05 (+0.66%)
Log in
NASDAQ:DMTK

DermTech Stock Forecast, Price & News

$11.30
+0.11 (+0.98 %)
(As of 10/19/2020 12:00 AM ET)
Add
Compare
Today's Range
$11.14
Now: $11.30▼
$11.59
50-Day Range
$10.23
MA: $11.18▼
$12.09
52-Week Range
$6.09
Now: $11.30▼
$16.95
Volume27,586 shs
Average Volume88,910 shs
Market Capitalization$220.36 million
P/E RatioN/A
Dividend YieldN/A
Beta0.74
DermTech, Inc., a molecular diagnostic company, develops and markets novel non-invasive diagnostic tests to diagnosis skin cancer and related conditions in the United States. The company offers Pigmented Lesion Assay (PLA), a gene expression test that helps rule out melanoma and the need for a surgical biopsy of atypical pigmented lesions. It also provides Nevome test, an adjunctive reflex test for the PLA; and adhesive skin sample collection kits, as well as gene expression assays for the Th1, Th2, IFN-gamma, and Th17 inflammatory pathways. The company is also developing non-melanoma skin cancer diagnostic and non-melanoma skin cancer risk assessment products. The company sells its products primarily to pathology and oncology practitioners. DermTech, Inc. is headquartered in La Jolla, California.
Read More

Beat the Market (BTM) Rank™

Analyst Opinion: 3.5Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank™

1.61 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:DMTK
Previous Symbol
CUSIPN/A
CIKN/A
Webwww.dermtech.com
Phone858-450-4222
Employees60

Debt

Debt-to-Equity RatioN/A
Current Ratio10.84
Quick Ratio10.82

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$3.36 million
Price / Sales65.58
Cash FlowN/A
Price / Cash FlowN/A
Book Value$1.01 per share
Price / Book11.19

Profitability

EPS (Most Recent Fiscal Year)($2.81)
Net Income$-19,690,000.00
Net Margins-599.76%
Return on Equity-69.48%
Return on Assets-60.96%

Miscellaneous

Outstanding Shares19,501,000
Market Cap$220.36 million
Next Earnings Date11/5/2020 (Estimated)
OptionableNot Optionable
$11.30
+0.11 (+0.98 %)
(As of 10/19/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive DMTK News and Ratings via Email

Sign-up to receive the latest news and ratings for DMTK and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











DermTech (NASDAQ:DMTK) Frequently Asked Questions

How has DermTech's stock been impacted by COVID-19?

DermTech's stock was trading at $14.37 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, DMTK stock has decreased by 21.4% and is now trading at $11.30.
View which stocks have been most impacted by COVID-19.

Do Wall Street analysts recommend investors buy shares of DermTech?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for DermTech in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for DermTech.

When is DermTech's next earnings date?

DermTech is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020.
View our earnings forecast for DermTech.

How were DermTech's earnings last quarter?

DermTech, Inc. (NASDAQ:DMTK) announced its quarterly earnings results on Wednesday, August, 5th. The company reported ($0.58) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.37) by $0.21. The company earned $0.84 million during the quarter. DermTech had a negative return on equity of 69.48% and a negative net margin of 599.76%.
View DermTech's earnings history.

What price target have analysts set for DMTK?

3 brokers have issued twelve-month price targets for DermTech's stock. Their forecasts range from $20.00 to $24.00. On average, they expect DermTech's stock price to reach $22.00 in the next twelve months. This suggests a possible upside of 94.7% from the stock's current price.
View analysts' price targets for DermTech.

Are investors shorting DermTech?

DermTech saw a increase in short interest in September. As of September 15th, there was short interest totaling 299,700 shares, an increase of 34.0% from the August 31st total of 223,600 shares. Based on an average daily trading volume, of 140,600 shares, the short-interest ratio is presently 2.1 days.
View DermTech's Short Interest.

Who are some of DermTech's key competitors?

Some companies that are related to DermTech include RadNet (RDNT), Fulgent Genetics (FLGT), ALX Oncology (RNLX), Progenity (PROG), Centogene (CNTG), Enzo Biochem (ENZ), Biocept (BIOC), Celcuity (CELC), OpGen (OPGN), Anpac Bio-Medical Science (ANPC), Miragen Therapeutics (MGEN), Psychemedics (PMD), American Shared Hospital Services (AMS), American Shared Hospital Services (AMS) and Avant Diagnostics (AVDX).
View all competitors.

What other stocks do shareholders of DermTech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other DermTech investors own include Pfizer (PFE), CrowdStrike (CRWD), Docusign (DOCU), ONEOK (OKE), Intel (INTC), US Xpress Enterprises (USX), Valero Energy (VLO), Momo (MOMO), AVEO Pharmaceuticals (AVEO) and Camping World (CWH).

Who are DermTech's key executives?

DermTech's management team includes the following people:
  • Dr. John D. Dobak, Pres, CEO & Director (Age 54, Pay $1.21M)
  • Dr. Burkhard Jansen, Chief Medical Officer (Age 54, Pay $419.8k)
  • Mr. Todd Michael Wood, Chief Commercial Officer (Age 51, Pay $700.12k)
  • Mr. Kevin Sun M.B.A., CFO, Treasurer & Sec. (Age 42)
  • Ms. Claudia Ibarra, Chief Operating Officer (Age 58)

What is DermTech's stock symbol?

DermTech trades on the NASDAQ under the ticker symbol "DMTK."

Who are DermTech's major shareholders?

DermTech's stock is owned by many different retail and institutional investors. Top institutional shareholders include Vigilare Wealth Management (0.06%). Company insiders that own DermTech stock include Claudia Ibarra, Enrico Picozza, John Dobak, Rtw Investments, Lp and Todd Michael Wood.
View institutional ownership trends for DermTech.

Which major investors are buying DermTech stock?

DMTK stock was bought by a variety of institutional investors in the last quarter, including Vigilare Wealth Management. Company insiders that have bought DermTech stock in the last two years include Enrico Picozza, and Rtw Investments, Lp.
View insider buying and selling activity for DermTech.

How do I buy shares of DermTech?

Shares of DMTK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is DermTech's stock price today?

One share of DMTK stock can currently be purchased for approximately $11.30.

How big of a company is DermTech?

DermTech has a market capitalization of $220.36 million and generates $3.36 million in revenue each year. The company earns $-19,690,000.00 in net income (profit) each year or ($2.81) on an earnings per share basis. DermTech employs 60 workers across the globe.

What is DermTech's official website?

The official website for DermTech is www.dermtech.com.

How can I contact DermTech?

DermTech's mailing address is 11099 N. Torrey Pines Road Suite 100, La Jolla CA, 92037. The company can be reached via phone at 858-450-4222 or via email at [email protected]

This page was last updated on 10/20/2020 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.